Judge Invalidates Allergan's Patent With SRMT
Share
Tweet
Four of the company’s patents covering its blockbuster eye drug Restasis were ruled invalid on Monday, October 16, 2017, by the US District Court for the Eastern District of Texas.
According to NPR, in the order on the agreement between Allergan and...
For access to this article please
sign in or
subscribe.
Reader Comments(0)